{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:19Z","timestamp":1791747919504,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:italic>Streptococcus pyogenes<\/jats:italic>infections continue to be a worldwide public health problem, causing various diseases in humans, with rheumatic fever and rheumatic heart disease being the most harmful manifestations. Impetigo and post-streptococcal glomerulonephritis are also important sequelae of skin infections. We have developed a candidate vaccine epitope (StreptInCor) that presents promising results in diverse animal models. To assess whether the StreptInCor alum-adsorbed vaccine could induce undesirable effects, a certified independent company conducted a repeated intramuscular dose toxicity evaluation in Wistar rats, a choice model for toxicity studies. We did not observe significant alterations in clinical, hematological, biochemical, anatomical, or histopathological parameters due to vaccine administration, even when the animals received the highest dose. In conclusion, repeated intramuscular doses did not show signs of macroscopic or other significant changes in the clinical or histopathological parameters, indicating that StreptInCor can be considered a safe candidate vaccine.<\/jats:p>","DOI":"10.3389\/fcvm.2021.643317","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T04:14:26Z","timestamp":1620706466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["StreptInCor, a Group A Streptococcal Adsorbed Vaccine: Evaluation of Repeated Intramuscular Dose Toxicity Testing in Rats"],"prefix":"10.3389","volume":"8","author":[{"given":"Luiz Carlos","family":"de S\u00e1-Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Maria Macruz Ferreira","family":"Demarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edilberto","family":"Postol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roney Orismar","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Elaine","family":"de Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Guilherme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, and national burden of rheumatic heart disease, 1990-2015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","article-title":"The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma","volume":"10","author":"Bowen","year":"2015","journal-title":"PLoS ONE."},{"key":"B3","doi-asserted-by":"publisher","first-page":"E557","DOI":"10.1542\/peds.2009-2648","article-title":"Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis","volume":"126","author":"Shaikh","year":"2010","journal-title":"Pediatrics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0140-6736(18)30999-1","article-title":"Acute rheumatic fever (vol 392, pg 161, 2018)","volume":"392","author":"Karthikeyan","year":"2018","journal-title":"Lancet."},{"key":"B5","first-page":"1007","article-title":"Rheumatic heart disease: 15 years of clinical and immunological follow-up","volume":"3","author":"Sampaio","year":"2007","journal-title":"Vasc Health Risk Manage."},{"key":"B6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.autrev.2015.04.005","article-title":"Post-infectious group A streptococcal autoimmune syndromes and the heart","volume":"14","author":"Martin","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1038\/nrdp.2015.84","article-title":"Acute rheumatic fever and rheumatic heart disease","volume":"2","author":"Carapetis","year":"2016","journal-title":"Nat Rev Dis Prim."},{"key":"B8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2174\/1389203718666170725115855","article-title":"Rheumatic heart disease: pathogenesis and vaccine","volume":"19","author":"Guilherme","year":"2018","journal-title":"Curr Protein Peptide Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1161\/01.CIR.83.6.1995","article-title":"Association of human-leukocyte class-II antigens with rheumatic-fever or rheumatic heart-disease in a brazilian population","volume":"83","author":"Guilherme","year":"1991","journal-title":"Circulation."},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1172\/JCI7132","article-title":"Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin","volume":"106","author":"Galvin","year":"2000","journal-title":"J Clin Investig."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.4049\/jimmunol.175.8.5448","article-title":"T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease","volume":"175","author":"Ellis","year":"2005","journal-title":"J Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17402520600877026","article-title":"Towards a vaccine against rheumatic fever","volume":"13","author":"Guilherme","year":"2006","journal-title":"Clin Dev Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3109\/08830185.2014.917411","article-title":"Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection","volume":"33","author":"Cunningham","year":"2014","journal-title":"Int Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.169.1.269","article-title":"Evidence for 2 distinct classes of streptococcal m-protein and their relationship to rheumatic-fever","volume":"169","author":"Bessen","year":"1989","journal-title":"J Exp Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.tim.2010.02.007","article-title":"The streptococcal M protein: a highly versatile molecule","volume":"18","author":"Smeesters","year":"2010","journal-title":"Trends Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E222","DOI":"10.1111\/1469-0691.12134","article-title":"Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study","volume":"19","author":"McMillan","year":"2013","journal-title":"Clin Microbiol Infect."},{"key":"B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.89.3.307","article-title":"Current knowledge of type-specific M antigens of group A streptococci","volume":"89","author":"Lancefield","year":"1962","journal-title":"J Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1128\/CMR.13.3.470","article-title":"Pathogenesis of group A streptococcal infections","volume":"13","author":"Cunningham","year":"2000","journal-title":"Clin Microbiol Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1086\/444505","article-title":"Prospects for a group a streptococcal vaccine: rationale, feasibility, and obstacles - report of a national institute of allergy and infectious diseases workshop","volume":"41","author":"Bisno","year":"2005","journal-title":"Clin Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.vaccine.2016.03.073","article-title":"Status of research and development of vaccines for Streptococcus pyogenes","volume":"34","author":"Steer","year":"2016","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0198658","DOI":"10.1371\/journal.pone.0198658","article-title":"Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial","volume":"13","author":"Sekuloski","year":"2018","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1016\/j.vaccine.2011.08.113","article-title":"HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate","volume":"29","author":"Guerino","year":"2011","journal-title":"Vaccine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e60969","DOI":"10.1371\/journal.pone.0060969","article-title":"StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice","volume":"8","author":"Postol","year":"2013","journal-title":"PLoS ONE."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1016\/j.vaccine.2013.08.043","article-title":"Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes","volume":"32","author":"De Amicis","year":"2014","journal-title":"Vaccine."},{"key":"B26","unstructured":"Princ\u00edpios das boas pr\u00e1ticas de laborat\u00f3rio \u2013 BPL. Norma N\u00b0 NIT-DICLA-0352011"},{"key":"B27","unstructured":"Series on Principles of Good Laboratory Practice and Compliance Monitoring. Number 1: Principles of Good Laboratory Practice1998"},{"key":"B28","unstructured":"Good Laboratory Practice Standards (40 CFR Ch.I-Part 160)1999"},{"key":"B29","first-page":"p. 220","volume-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9733","DOI":"10.1038\/s41598-019-46244-2","article-title":"Group A Streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs","volume":"9","author":"Postol","year":"2019","journal-title":"Sci Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ilar.37.3.93","article-title":"Review of polyclonal antibody production procedures in mammals and poultry","volume":"37","author":"Hanly","year":"1995","journal-title":"ILAR J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ilar.46.3.269","article-title":"Critical steps in the production of polyclonal and monoclonal antibodies evaluation and recommendations","volume":"46","author":"Leenaars","year":"2005","journal-title":"Ilar J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum Vaccines Immunother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1016\/j.vaccine.2013.05.107","article-title":"Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1189\/jlb.0607392","article-title":"Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production","volume":"83","author":"Wang","year":"2008","journal-title":"J Leukoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1016\/j.vaccine.2007.03.045","article-title":"Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants","volume":"25","author":"Sokolovska","year":"2007","journal-title":"Vaccine."},{"key":"B38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaut.2005.01.007","article-title":"How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease","volume":"24","author":"Fae","year":"2005","journal-title":"J Autoimmun."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.643317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:17:58Z","timestamp":1699024678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.643317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2021.643317"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.643317","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"article-number":"643317"}}